VIDEO: Alphyn Biologics’ atopic dermatitis candidate shows positive early results NEWS PROVIDED BY Alphyn Biologics Mar 21, 2023 In this Healio video exclusive from the American Academy of Dermatology Annual Meeting, Neal Koller, founder and CEO of Alphyn Biologics, discusses the clinical-stage company’s drug pipeline. View the video here. CONTACTS Corporate: Neal Koller…
Empowered Patient Podcast: Treating Atopic Dermatitis Using Therapeutic Drug Containing Multiple Bioactive Compounds with Neal Koller Alphyn Biologics NEWS PROVIDED BY Alphyn Biologics Feb 27, 2023 Neal Koller, CEO of Alphyn Biologics, discusses their first topical drug which treats both atopic dermatitis and atopic dermatitis with secondary infection. Listen to the podcast here. CONTACTS…
Cincinnati Business Courier: Queen City Angels-backed Alphyn eyes another fundraise amid ‘positive’ clinical study results by Liz Engel NEWS PROVIDED BY Alphyn Biologics January 11, 2023 Alphyn Biologics, a clinical-stage dermatology company developing a new class of drugs for skin diseases, will pursue a Series B financing round in 2023. Read the Cincinnati Business Courier…
Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Jan 4, 2023, 07:30 ET ANNAPOLIS, Md., Jan. 4, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today positive results from the first cohort of its Phase…
Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Nov 15, 2022, 07:30 ET ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it has completed the first cohort of its Phase2a…